Question 1

What is the difference between Tecentriq and Keytruda?

Accepted Answer

Tecentriq is Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system. and is developed by Roche. Keytruda is Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response. and is developed by Merck & Co..

Question 2

What are Tecentriq and Keytruda used for?

Accepted Answer

Tecentriq: Extensive stage primary small cell carcinoma of lung, Germline BRCA-mutated, HER2-negative metastatic breast cancer, Liver cell carcinoma. Keytruda: Melanoma, NSCLC (nonsquamous), NSCLC (squamous).

Question 3

Are Tecentriq and Keytruda in the same drug class?

Accepted Answer

No — Tecentriq is Programmed Death Receptor-1 Blocking Antibody [EPC] and Keytruda is Monoclonal antibody; PD-1 inhibitor.

	Tecentriq	Keytruda
Generic name	atezolizumab	pembrolizumab
Sponsor	Roche	Merck & Co.
Drug class	Programmed Death Receptor-1 Blocking Antibody [EPC]	Monoclonal antibody; PD-1 inhibitor
Molecular target	Programmed cell death 1 ligand 1	PD-1 receptor
Modality	Monoclonal antibody	Monoclonal antibody
Phase	FDA-approved	FDA-approved
Therapeutic area	Oncology	Oncology
First approval	2016	2014-09-04

Tecentriq vs Keytruda

At a glance

Mechanism of action

Approved indications

Tecentriq

Keytruda

Common side effects

Tecentriq

Keytruda

Further reading

Tecentriq	Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system.
Keytruda	Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response.